CLL Archives -

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic

TG Therapeutics challenges Roche with FDA filing for CLL drug

https://pharmaphorum.com/news/tg-therapeutics-challenges-roche-with-fda-filing-for-cll-drug/

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

George Underwood AstraZeneca, Calquence, chronic lymphocytic leukaemia, CLL, Lynparza, Merck & Co, MSD, ovarian cancer, PARP 0 Comment

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

https://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/

News/ News/ Oncology

AZ prepares for showdown with AbbVie/J&J as Calquence shines in CLL

Richard Staines AbbVie, AstraZeneca, cancer, CLL, Johnson & Johnson 0 Comment

AstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing

AZ prepares for showdown with AbbVie/J&J as Calquence shines in CLL

https://pharmaphorum.com/news/az-prepares-for-showdown-with-abbvie-jj-as-calquence-shines-in-cll/

News/ News/ Oncology

Roche and AbbVie’s Venclexta approved in CLL

George Underwood AbbVie, CLL, Genentech, leukaemia, Roche, Venclexta, venetoclax 0 Comment

Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for

Roche and AbbVie’s Venclexta approved in CLL

https://pharmaphorum.com/news/roche-and-abbvies-venclexta-approved-in-cll/

News/ News/ R&D

AbbVie/Roche seek first-line CLL use for Venclexta combo

Phil Taylor AbbVie, CLL, Roche, Venclexta 0 Comment

AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new

AbbVie/Roche seek first-line CLL use for Venclexta combo

https://pharmaphorum.com/news/abbvie-roche-seek-first-line-cll-use-for-venclexta-combo/

News/ News/ R&D

AbbVie and J&J claim new Imbruvica okay in US

Phil Taylor AbbVie, CLL, Imbruvica, Johnson & Johnson 0 Comment

AbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL)

AbbVie and J&J claim new Imbruvica okay in US

https://pharmaphorum.com/news/abbvie-and-jj-claim-new-imbruvica-okay-in-us/

News/ UK & Europe

Roche’s Mabthera faces cut-price competition in EU

Richard Staines AbbVie, Amgen, Biogen, biosimilar, blood cancer, cancer, Celltrion, CLL, inflammatory diseases, NHL, Rheumatoid arthritis, Roche 0 Comment

Blockbuster likely to face cheap near-copy for first time.

Roche’s Mabthera faces cut-price competition in EU

https://pharmaphorum.com/news/roches-mabthera-faces-cut-price-competition-eu/

AbbVie/ News/ UK & Europe

AbbVie’s Venclyxto approved in Europe in CLL

Richard Staines AbbVie, blood cancer, cancer, chronic lymphocytic leukaemia, CLL 0 Comment

AbbVie blood cancer drug tipped to be a blockbuster.

AbbVie’s Venclyxto approved in Europe in CLL

https://pharmaphorum.com/news/abbvies-venclyxto-approved-europe-cll/

AbbVie/ News/ Rare diseases/ Sales and Marketing/ UK & Europe

AbbVie’s CLL drug recommended in Europe

Richard Staines AbbVie, blood cancer, chronic lymphocytic leukaemia, CLL, Gilead, Janssen 0 Comment

Leukaemia drug likely to get conditional approval.

AbbVie’s CLL drug recommended in Europe

https://pharmaphorum.com/news/eu-regulators-back-abbvie-drug-cll/

Trending

CLL

Login